| アブストラクト | We describe the safety profiles of all drug classes used for the treatment of advanced melanoma from the US Food and Drug Administration Adverse Event Reporting System over 2008-2018. Adverse reactions reported in 25 900 pharmacovigilance cases are described for chemotherapies, immunomodulators, targeted therapies and immunotherapies. There was a sharp increase in the number of cases over time, with peaks associated with the launch of new treatments. The adverse reactions diversified over time; notably, skin (alopecias, dermatitis) and retinal disorders were frequently associated with targeted therapies and endocrine disorders (hypothalamus, thyroid and adrenal dysfunctions) with immunotherapies. Less well-known reactions were also detected, such as neuropsychiatric disorders with targeted therapies and gastrointestinal ulcers, pneumothorax and pleural effusions with immunotherapies. The findings highlight the need for various health professionals (including medical specialists or trained nurses) to enhance management of complications. |
|---|
| ジャーナル名 | British journal of clinical pharmacology |
|---|
| Pubmed追加日 | 2020/12/10 |
|---|
| 投稿者 | Casarotto, Emilie; Noize, Pernelle; Letinier, Louis; Salvo, Francesco; Pham-Ledard, Anne; Molimard, Mathieu |
|---|
| 組織名 | Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology,;UMR 1219, Univ. Bordeaux, Bordeaux, France.;Department of Pharmacology, Bordeaux University Hospital, Bordeaux, France.;Department of Dermatology, Bordeaux University Hospital and Univ. Bordeaux,;Bordeaux, France. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/33294983/ |
|---|
